Testolone, also known by its research code RAD-140, is an investigational compound categorized as a selective androgen receptor modulator (SARM). SARMs are a class of therapeutic compounds that aim to have similar effects to androgenic drugs like anabolic steroids but with potentially fewer side effects. Testolone selectively binds to androgen receptors in certain tissues, such as muscle and bone, with less activity in other tissues like the prostate. This selectivity is intended to promote anabolic effects (e.g., increased muscle mass and bone density) while minimizing androgenic side effects (e.g., prostate enlargement, hair loss) often associated with traditional anabolic steroids (NIH ODS, PubChem). Testolone is not approved for human use by regulatory bodies like the U.S. Food and Drug Administration (FDA) and is still undergoing research to determine its full profile, including efficacy, safety, and long-term effects. It is often marketed and discussed in contexts related to bodybuilding and athletic performance enhancement, despite the lack of clinical approval for such uses. Its half-life is estimated to be approximately 60 hours.
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
["National Institutes of Health (NIH) Office of Dietary Supplements (ODS)","MedlinePlus (via NIH)","PubChem (National Library of Medicine)","U.S. Food and Drug Administration (FDA) Public Warnings","DrugBank"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the hormone category or studied for the same goals.